[SMLE] A Unique Case of Non-paraneoplastic Lambert-Eaton Myasthenic Syndrome Treated With Subcutaneous Immunoglobulin: A
Posté : 21 juin 2024 12:00
Cureus. 2024 May 21;16(5):e60773. doi: 10.7759/cureus.60773. eCollection 2024 May.
ABSTRACT
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune neuromuscular disorder caused by pathogenic autoantibodies directed against voltage-gated calcium channels present on the presynaptic nerve terminal. For LEMS patients refractory to initial symptomatic treatment with amifampridine, immunomodulatory therapy with intravenous immunoglobulin (IVIG) is often utilized. However, in the authors' review of literature, the utility of subcutaneous immunoglobulin (SCIG) in the treatment of LEMS has been scarcely reported. Here, we present a unique case of non-paraneoplastic LEMS managed with SCIG with excellent clinical response and improvement on electromyography. SCIG therapy may be a reasonable alternative for patients with LEMS who do not tolerate the intravenous formulation.
PMID:38903354 | PMC:PMC11188003 | DOI:10.7759/cureus.60773
Source: https://pubmed.ncbi.nlm.nih.gov/3890335 ... t9+e462414